
    
      HBsAg Positive lymphoma patients are treated with entecavir when they receive rituximab-based
      immunochemotherapy. Entecavir 0.5mg daily is administrated from day 1 of immunochemotherapy
      and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.
    
  